1. Home
  2. SMX vs MREO Comparison

SMX vs MREO Comparison

Compare SMX & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SMX (Security Matters) Public Limited Company

SMX

SMX (Security Matters) Public Limited Company

HOLD

Current Price

$140.66

Market Cap

348.8M

Sector

Technology

ML Signal

HOLD

Logo Mereo BioPharma Group plc

MREO

Mereo BioPharma Group plc

HOLD

Current Price

$2.18

Market Cap

324.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMX
MREO
Founded
N/A
2015
Country
Ireland
United Kingdom
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
348.8M
324.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SMX
MREO
Price
$140.66
$2.18
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.50
AVG Volume (30 Days)
3.8M
2.2M
Earning Date
01-01-0001
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$131.12
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.12
$1.47
52 Week High
$66,187.38
$3.90

Technical Indicators

Market Signals
Indicator
SMX
MREO
Relative Strength Index (RSI) 56.14 62.28
Support Level $96.01 $2.02
Resistance Level $272.00 $2.37
Average True Range (ATR) 67.82 0.15
MACD 8.03 0.04
Stochastic Oscillator 28.48 69.05

Price Performance

Historical Comparison
SMX
MREO

About SMX SMX (Security Matters) Public Limited Company

SMX (Security Matters) PLC provides one solution to solve both authentication and track and trace challenges in order to uphold supply chain integrity and provide quality assurance and brand accountability to producers of goods. Its technology works as a track and trace system using a marker, a reader, and an algorithm to identify embedded sub-molecular particles in order to track and trace different components along a production process (or any other marked good along a supply chain) to the end producer.

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Share on Social Networks: